Navigation Links
Honeywell Introduces New Ultra-High Barrier Film for Pharmaceutical Packaging
Date:10/17/2011

MORRIS TOWNSHIP, N.J., Oct. 17, 2011 /PRNewswire/ -- Honeywell (NYSE: HON) today introduced a new pharmaceutical packaging film that provides the highest moisture barrier of any film of its type.

Part of the Aclar® family of films, the new product, Aclar UltRx 6000, is effective at protecting moisture-sensitive medicines in all climates, even the hottest and most humid locations. This allows pharmaceutical companies to standardize their product packaging with one solution that will work in all regions of the world.

Aclar films, including Aclar UltRx 6000, can also help reduce drug package sizes by up to 55 percent compared with the alternative, cold-formed foil. Aclar UltRx 6000 can be used in existing equipment, with only minor adjustments, that pharmaceutical companies use to thermoform their packages. Also, like all Aclar films, Aclar UltRx 6000 is clear, allowing pharmaceutical companies to differentiate their brand by allowing the pill to be seen through the packaging.

"This Aclar film gives pharmaceutical companies a clear, ultra-high barrier choice for their most moisture-sensitive drugs sold in the most challenging regions," said Jeff Czarnecki, global leader of Honeywell's health care and packaging business. "This new film will help pharmaceutical companies around the world protect their medicines, simplify their supply chains, and improve their branding."

Aclar UltRx 6000 is a 6 mil, 152 micron thermoformable film that provides an extremely low water/moisture vapor transmission rate (WVTR/MVTR). This property helps protect drugs especially in climatic Zones 4 and 4B, which includes many parts of South America, Africa, India, and Southeast Asia.  

According to IMS Health, an information services provider for the healthcare industry, the pharmaceuticals market in emerging regions, including several Zone IV countries, is expected to grow by 14 to 17 percent through 2014.

Honeywell Aclar thermoformable films have been trusted by the world's largest pharmaceutical companies for more than 40 years. Aclar films have excellent moisture barrier and chemical stability properties. They are crystal clear, biochemically inert, chemical-resistant, nonflammable, and plasticizer- and stabilizer-free.

Aclar films are based on polychlorotrifluoroethylene (PCTFE) fluoropolymer technology. They can facilitate increased patient compliance with doctor prescriptions with see-through, portable and patient-friendly pack presentations.

For more information, visit www.aclaradvantage.com/ultrx6000.

Honeywell Specialty Materials is a global leader in providing customers with high-performance specialty materials, including fluorine products; specialty films and additives; advanced fibers and composites; intermediates; specialty chemicals; electronic materials and chemicals; and technologies and materials for petroleum refining.

Honeywell International (www.honeywell.com) is a Fortune 100 diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London, and Chicago Stock Exchanges.  For more news and information on Honeywell, please visit www.honeywellnow.com.

This release contains certain statements that may be deemed "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, that address activities, events or developments that we or our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this release are also subject to a number of material risks and uncertainties, including but not limited to economic, competitive, governmental, and technological factors affecting our operations, markets, products, services and prices. Such forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by such forward-looking statements.


'/>"/>
SOURCE Honeywell
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey
2. Yamhill County Introduces Prescription Discount Card to Help Alleviate High Costs
3. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
4. Verathon Introduces the GlideScope AVL Reusable Video Laryngoscope;
5. Fukuda Denshi Introduces the UF-760AG Color Portable Ultrasound System in the U.S.
6. Waters Introduces New TruView LCMS Certified Vials for the Analytical Laboratory
7. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
8. Ethicon Endo-Surgery Introduces First Powered Endocutter with Enhanced System-Wide Compression and Stability, Allowing Surgeons Greater Control in Laparoscopic Surgery
9. Cardinal Health Introduces New Latex, Powder-Free, Hydrogel Surgical Gloves
10. Sensitech Inc. Introduces Temperature and Humidity Monitor for Flammable and Hazardous Environments
11. IntelligentMDx (IMDx) Introduces a CE-Marked Automated Molecular Test for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant Enterococci
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology:
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Fisher House Foundation ... Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns ... the VA Southern Nevada Healthcare System. This will be the first Fisher House ...
(Date:2/12/2016)... ... 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, PhD ... . The list consists of physicians establishing, leading and partnering with ambulatory surgery centers ... An Ambulatory Surgery Center, also known as an ASC, is a modern health care ...
(Date:2/12/2016)... ... 12, 2016 , ... Donor Network West, the organ procurement organization that heals ... with San Ramon Regional Medical Center. Under the collaboration, the first of its kind, ... accommodate a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... surrounding communities by continuing it’s commitment to act as Agents of Change in ... works closely with area homeless families to fulfill immediate needs and help them ...
Breaking Medicine News(10 mins):